Literature DB >> 18388744

Methadone: does it really have low efficacy at micro-opioid receptors?

Ivan Rodriguez-Martin1, Ellen Braksator, Chris P Bailey, Sam Goodchild, Neil V Marrion, Eamonn Kelly, Graeme Henderson.   

Abstract

There is confusion in the literature concerning the relative agonist efficacy of methadone at micro-opioid receptors (MOPrs). Here, we confirm that methadone is a full agonist in guanosine 5'-O-[gamma-thio]triphosphate (GTPgammaS) binding studies. Methadone, however, seems to have low efficacy in studies of MOPr activation of G-protein-gated potassium (GIRK) channels, but this is because it directly inhibits the GIRK channels. Methadone also inhibits alpha2-adrenoceptor-activated GIRK channels. Methadone is not a specific GIRK channel blocker. It also inhibits small conductance Ca2+-activated K+ (SK2) channels. We conclude that methadone is a full agonist at MOPrs that, as we and others have shown, induces MOPr desensitization and internalization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388744     DOI: 10.1097/WNR.0b013e3282f97b64

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

1.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

Review 2.  Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons.

Authors:  Vu C Dang; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Activation of µ-opioid receptors and block of Kir3 potassium channels and NMDA receptor conductance by L- and D-methadone in rat locus coeruleus.

Authors:  Aya Matsui; John T Williams
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

4.  Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone.

Authors:  Nidia Quillinan; Elaine K Lau; Michael Virk; Mark von Zastrow; John T Williams
Journal:  J Neurosci       Date:  2011-03-23       Impact factor: 6.167

Review 5.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

6.  Differential activation and trafficking of micro-opioid receptors in brain slices.

Authors:  Seksiri Arttamangkul; Nidia Quillinan; Malcolm J Low; Mark von Zastrow; John Pintar; John T Williams
Journal:  Mol Pharmacol       Date:  2008-07-08       Impact factor: 4.436

7.  Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone.

Authors:  Tarek Z Deeb; Douglas Sharp; Tim G Hales
Journal:  Mol Pharmacol       Date:  2009-01-08       Impact factor: 4.436

8.  Does PKC activation increase the homologous desensitization of μ opioid receptors?

Authors:  Seksiri Arttamangkul; William Birdsong; John T Williams
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

9.  μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons.

Authors:  Mahsa Sadeghi; Thomas M Tzschentke; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

10.  Ethanol Reversal of Tolerance to the Respiratory Depressant Effects of Morphine.

Authors:  Rob Hill; Abi Lyndon; Sarah Withey; Joanne Roberts; Yvonne Kershaw; John MacLachlan; Anne Lingford-Hughes; Eamonn Kelly; Chris Bailey; Matthew Hickman; Graeme Henderson
Journal:  Neuropsychopharmacology       Date:  2015-07-14       Impact factor: 7.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.